Abstract
Protein kinase C (PKC) is a family of kinases that plays diverse roles in many cellular functions, notably proliferation, differentiation, and cell survival. PKC is processed by phosphorylation and regulated by cofactor binding and subcellular localization. Extensive detail is available on the molecular mechanisms that regulate the maturation, activation, and signaling of PKC. However, less information is available on how signaling is terminated both from a global perspective and isozyme-specific differences. To target PKC therapeutically, various ATP-competitive inhibitors have been developed, but this method has problems with specificity. One possible new approach to developing novel, specific therapeutics for PKC would be to target the signaling termination pathways of the enzyme. This review focuses on the new developments in understanding how PKC signaling is terminated and how current drug therapies as well as information obtained from the recent elucidation of various PKC structures and down-regulation pathways could be used to develop novel and specific therapeutics for PKC.
Keywords: family kinases, Protein Kinase C, cellular functions, proliferation, phosphorylation, molecular mechanisms, signaling termination pathways, current drug therapies
Current Drug Targets
Title: The Life and Death of Protein Kinase C
Volume: 9 Issue: 8
Author(s): Christine M. Gould and Alexandra C. Newton
Affiliation:
Keywords: family kinases, Protein Kinase C, cellular functions, proliferation, phosphorylation, molecular mechanisms, signaling termination pathways, current drug therapies
Abstract: Protein kinase C (PKC) is a family of kinases that plays diverse roles in many cellular functions, notably proliferation, differentiation, and cell survival. PKC is processed by phosphorylation and regulated by cofactor binding and subcellular localization. Extensive detail is available on the molecular mechanisms that regulate the maturation, activation, and signaling of PKC. However, less information is available on how signaling is terminated both from a global perspective and isozyme-specific differences. To target PKC therapeutically, various ATP-competitive inhibitors have been developed, but this method has problems with specificity. One possible new approach to developing novel, specific therapeutics for PKC would be to target the signaling termination pathways of the enzyme. This review focuses on the new developments in understanding how PKC signaling is terminated and how current drug therapies as well as information obtained from the recent elucidation of various PKC structures and down-regulation pathways could be used to develop novel and specific therapeutics for PKC.
Export Options
About this article
Cite this article as:
Gould M. Christine and Newton C. Alexandra, The Life and Death of Protein Kinase C, Current Drug Targets 2008; 9 (8) . https://dx.doi.org/10.2174/138945008785132411
DOI https://dx.doi.org/10.2174/138945008785132411 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Adverse Effects of Statins - Myths and Reality
Current Pharmaceutical Design PLCO: Evolution of an Epidemiologic Resource and Opportunities for Future Studies
Reviews on Recent Clinical Trials Juglone Exerts Cytotoxic, Anti-proliferative and Anti-invasive Effects on Glioblastoma Multiforme in a Cell Culture Model
Anti-Cancer Agents in Medicinal Chemistry HOX Genes as Potential Markers of Circulating Tumour Cells
Current Molecular Medicine Implications of Photophysical and Physicochemical Factors on Successful Application of Photodynamic Therapy
Current Pharmaceutical Design Interactions of Cisplatin with non-DNA Targets and their Influence on Anticancer Activity and Drug Toxicity: The Complex World of the Platinum Complex
Current Cancer Drug Targets Perspectives in Breast and Ovarian Cancer Chemotherapy by Nanomedicine Approach: Nanoformulations in Clinical Research
Current Medicinal Chemistry Redox Regulation in the Base Excision Repair Pathway: Old and New Players as Cancer Therapeutic Targets
Current Medicinal Chemistry Qigefang Inhibits Migration, Invasion, and Metastasis of ESCC by Inhibiting Gas6/Axl Signaling Pathway
Recent Patents on Anti-Cancer Drug Discovery Adhesion Molecules as Targets for the Treatment of Neoplastic Diseases
Current Pharmaceutical Design The Redox Biology of Schistosome Parasites and Applications for Drug Development
Current Pharmaceutical Design Current Clinical Applications of In Vivo Magnetic Resonance Spectroscopy and Spectroscopic Imaging
Current Medical Imaging The Role of Survivin for Radiation Oncology: Moving Beyond Apoptosis Inhibition
Current Medicinal Chemistry A Novel Platinum-based Compound with Preferential Cytotoxic Activity against a Panel of Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Viral Based Gene Therapy for Prostate Cancer
Current Gene Therapy NSAIDs and Chemoprevention
Current Cancer Drug Targets Nanoparticle Systems Modulating Myeloid-Derived Suppressor Cells for Cancer Immunotherapy
Current Topics in Medicinal Chemistry Influence of Aldo-keto Reductase 1C3 in Prostate Cancer - A Mini Review
Current Cancer Drug Targets Cancer Stem Cells: A New Paradigm for Understanding Tumor Growth and Progression and Drug Resistance
Current Medicinal Chemistry Epigenetic Changes Induced by Green Tea Catechins a re Associated with Prostate Cancer
Current Molecular Medicine